ArticleCurrent pharmaceutical biotechnology2024
Optimization of Phloretin-loaded Nanospanlastics for Targeting of
Article in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Naringenin-loaded nanoparticles ameliorate scopolamine-induced neurotoxicity.Scientific reports · 2026Article
- Design and Synthesis of Novel Spiropyridine Derivatives as Promising Anti-inflammatory and Gene-targeting Agents Against COVID-19.Current pharmaceutical design · 2026Article
- Nutritional Evaluation and Free Radical Scavenging Activity of Nano-formulated Selenium-Moringa Peregrine Seed Extract as a Promising Suppressor of TGF-β1/P38/NF-kβ Signaling Pathway in HgClCurrent pharmaceutical biotechnology · 2026Article
- Moringa Peregrina-derived Selenium Nanoparticles: Potent Inhibitor of Key Inflammatory Pathways in Aluminum-exposed Rats.Pharmaceutical nanotechnology · 2026Article
- Ferulic acid-loaded chitosan nanoparticles enhance radiotherapy efficacy via STAT3 suppression and caspase-8/p53 activation in Ehrlich ascites carcinoma.Scientific reports · 2025Article
- Phloretin-nanospanlastics for targeting the Akt/PI3K signaling pathways in dimethylhydrazine-induced colon cancer in mice.International journal of pharmaceutics: X · 2025Article
- Vitexin's Role in Colon Cancer Apoptosis: AMPK/mTOR Pathway Modulation Explored Through Experimental and Computational Approaches.Recent patents on anti-cancer drug discovery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesObese patients are at increased risk for CVD, which is the main cause of premature death and has been a major cause of disability and ill health in recent years. PTN, a natural dihydrochalcone flavonoid, has a variety of pharmacological characteristics. This article aimed to prepare PTN-NSLs to evaluate their anti-obesity activity.
methodsMorphology, Particle size, zeta potential, UV-vis, entrapment efficiency, FT-IR spectra, and an
resultsThe synthesized PTN-NSLs were uniform, spherically shaped, and well dispersed with no aggregation noted, with a size range of 114.06 ± 8.35 nm. The measured zeta potential value of PTN-NSLs was -32.50.8 mv. Also, the UV spectra of PTN and PTN-NSLs have strong absorption at 225 and 285 nm. Also, the LD
conclusionAdministration of PTN-NSLs significantly attenuated the levels of glycemic, oxidative stress, and inflammatory biomarkers. The biochemical and PCR findings are aided by histological investigations. Also, the present findings imply that PTN-NSLs might be a promising pharmacological tool for the treatment of obesity-related diseases.
Indexed as
Identifiers
38698746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.